小细胞肺癌放疗:ASTRO临床实践指南
美国放射肿瘤学会(ASTRO)针对局限期与广泛期小细胞肺癌(SCLC)的胸部放疗和预防性颅脑照射(PCI)制定指南,基于系统文献综述与共识方法回答4个关键问题。指南强烈推荐局限期患者早期行每日一次或两次的根治性胸部放疗,并对广泛期患者选择性地推荐胸部放疗及PCI决策咨询。
要点
- 局限期SCLC强烈推荐早期根治性胸部放疗,每日一次或两次。
- I/II期淋巴结阴性者可选择SBRT或常规分割,化疗在SBRT前后进行。
- 广泛期SCLC化疗后选择性患者强烈推荐胸部放疗,并咨询PCI与MRI监测。
核心结论
- 放疗在局限期和广泛期SCLC中均起重要作用,指南为SCLC局部治疗提供最佳临床实践依据。
研究设计与样本
- ASTRO召集工作组,基于系统文献综述和共识构建方法及证据质量与推荐强度分级系统制定,聚焦4个关键问题。
主要发现
- 局限期SCLC强烈推荐治疗早期行每日一次或两次根治性胸部放疗;术后切缘阳性或淋巴结转移者条件推荐辅助放疗。
- 强烈推荐采用适形先进技术行累及野放疗,照射化疗后体积;I/II期淋巴结阴性者强烈推荐SBRT或常规分割。
- 局限期II/III期化疗放疗有效者强烈推荐PCI,I期条件不推荐,神经认知毒性高风险者应共同决策。
- 广泛期强烈推荐放疗科医生会诊以考虑PCI对比磁共振监测;化疗后选择性患者强烈推荐胸部放疗,化疗及免疫治疗有效者条件推荐。
关键数值与推荐
- 局限期SCLC:根治性胸部放疗每日一次或两次,治疗早期给予(强烈推荐)。
- 局限期I/II期淋巴结阴性:SBRT或常规分割强烈推荐,化疗在SBRT前或后给予。
- 局限期II/III期化疗放疗有效者:PCI强烈推荐;I期条件不推荐。
- 广泛期:放疗科医生会诊讨论PCI对比磁共振监测强烈推荐。
- 广泛期化疗后选择性患者:胸部放疗强烈推荐,化疗和免疫治疗有效者条件推荐。
临床怎么用
- 局限期SCLC应尽早启动根治性胸部放疗并采用适形累及野技术照射化疗后体积。
- I/II期淋巴结阴性患者可与SBRT或常规分割间选择,并安排化疗时序。
- 广泛期患者需放疗科会诊评估PCI与MRI监测,化疗后选择性行胸部放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence for thoracic RT and prophylactic cranial irradiation (PCI) for both limited-stage (LS) and extensive-stage (ES) SCLC. METHODS: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on indications, dose fractionation, techniques and timing of thoracic RT for LS-SCLC, the role of stereotactic body radiation therapy (SBRT) compared with conventional RT in stage I or II node negative SCLC, PCI for LS-SCLC and ES-SCLC, and thoracic consolidation for ES-SCLC. Recommendations were based on a systematic literature review and created using a consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS: The task force strongly recommends definitive thoracic RT administered once or twice daily early in the course of treatment for LS-SCLC. Adjuvant RT is conditionally recommended in surgically resected patients with positive margins or nodal metastases. Involved field RT delivered using conformal advanced treatment modalities to postchemotherapy volumes is also strongly recommended. For patients with stage I or II node negative disease, SBRT or conventional fractionation is strongly recommended, and chemotherapy should be delivered before or after SBRT. In LS-SCLC, PCI is strongly recommended for stage II or III patients who responded to chemoradiation, conditionally not recommended for stage I patients, and should be a shared decision for patients at higher risk of neurocognitive toxicities. In ES-SCLC, radiation oncologist consultation for consideration of PCI versus magnetic resonance surveillance is strongly recommended. Lastly, the use of thoracic RT is strongly recommended in select patients with ES-SCLC after chemotherapy treatment, including a conditional recommendation in those responding to chemotherapy and immunotherapy. CONCLUSIONS: RT plays a vital role in both LS-SCLC and ES-SCLC. These guidelines inform best clinical practices for local therapy in SCLC.
引用
- Simone CB, Bogart JA, Cabrera AR, et al. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2020. PMID: 32222430. doi:10.1016/j.prro.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。